Smithsonian Magazine on MSN
Women are more likely to have irritable bowel syndrome. This newfound gut pain pathway might explain why
Between 25 million and 45 million people in the United States live with irritable bowel syndrome (IBS), a chronic disorder ...
Irritable bowel syndrome (IBS) is a chronic condition that causes gut pain and bloating, and women are far more likely to ...
Giredestrant shows significant improvement in iDFS in patients with early-stage, HR-positive, HER2-negative breast cancer.
Triple-positive breast cancer involves tumors positive for estrogen, progesterone, and HER2 receptors, affecting treatment decisions and strategies. Diagnosis includes imaging and biopsy to confirm ...
Athira Pharma has joined an attempt to rescue an asset abandoned by Pfizer. The biotech has secured near-global rights to a phase 3 breast cancer prospect in a deal with Sermonix Pharmaceuticals.
News-Medical.Net on MSN
Estrogen drives gut pain and explains higher rates of IBS in women
Women are dramatically more likely than men to suffer from irritable bowel syndrome (IBS), a chronic condition causing ...
Hormone therapies have played a major role in improving survival for patients with ER+ breast cancer [1]. By blocking or reducing estrogen’s impact, these treatments slow the cancer’s growth and help ...
Many breast cancer drugs block estrogen receptors inside cancer cells. Blocking the receptors early in disease progression staves off metastasis. But most patients with advanced disease eventually ...
Phytoestrogens are plant-derived compounds that weakly mimic estrogen, supporting collagen, hydration and repair in ageing skin while promoting hormonal balance. | Mind and Body, Menopause ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback